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doi:10.1016/j.jtcvs.2003.11.058Objective: Cardiopulmonary bypass and surgical stress are accompanied by a
systemic inflammatory response and activation of coagulation. Thrombin forms
fibrin and activates platelets and neutrophils. Consequently, disseminated micro-
thrombosis might increase capillary vascular resistance and thus impair reperfusion.
We hypothesized that recombinant hirudin, a direct inhibitor of thrombin, could
attenuate coagulation and enhance microvascular flow during reperfusion.
Methods: Twenty pigs undergoing 60 minutes of aortic clamping and 75 minutes of
normothermic perfusion were randomized in a blinded setting to receive an intra-
venous bolus of recombinant hirudin (10 mg, 0.4 mg/kg; n  10) or placebo (n 
10) 15 minutes before aortic declamping and then continued with an intravenous
135-minute infusion of recombinant hirudin (3.75 mg/h, 0.15 mg/kg) or placebo.
Thrombin-antithrombin complexes, activated clotting times, and several hemody-
namic parameters were measured before cardiopulmonary bypass, after weaning
from cardiopulmonary bypass, and at 30, 60, 90, and 120 minutes after aortic
declamping. Intramucosal pH and PCO2 were measured from the luminal surface of
ileum simultaneously with arterial gas analysis at 30-minute intervals.
Results: Recombinant hirudin inhibited thrombin formation after aortic declamping;
at 120 minutes, thrombin-antithrombin complexes levels (g/L, mean  SD) were
75  21 and 29  44 (P  .001) for placebo and pigs receiving recombinant
hirudin, respectively. When compared with the placebo group, pigs receiving
recombinant hirudin showed significantly higher stroke volume, cardiac output, and
lower systemic vascular resistance at 60 and 90 minutes after aortic declamping (P
 .05). Based on arteriomucosal PCO2 and pH differences, progressive worsening of
intestinal microcirculatory perfusion occurred in the placebo group but not in the
recombinant hirudin group.
Conclusion: Infusion of thrombin inhibitor recombinant hirudin during reperfusion
was associated with attenuated postischemia left ventricular dysfunction and de-
creased vascular resistance. Consequently microvascular flow was improved during
ischemia-reperfusion injury. Control of thrombin formation during reperfusion may
be a feasible approach to improve oxygen delivery to reperfused vascular beds.
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CSPIn cardiac surgery cardiopulmonary bypass (CPB)and surgical stress are accompanied by a systemicinflammatory response,1-3 which results in activa-tion and interaction of several humoral amplifica-tion systems. Aortic clamping causes global myo-cardial ischemia but CPB can also cause
hypoperfusion of various organs. Although CPB maintains
splanchnic circulation, low pumping pressure, nonpulsatile
perfusion, and hypothermia lead to splanchnic hypoperfu-
sion and ischemia.4-6 Restoration of myocardial blood flow
and normal circulation conditions to hypoperfused areas
results in ischemia-reperfusion injury.
Ischemia-reperfusion injury is initiated by overlapping
cascades of inflammatory mediators at systemic and local
levels causing an acute inflammatory response and activa-
tion of coagulation in postischemic tissues.7-10 Postischemic
endothelium becomes activated and expresses proinflamma-
tory and procoagulatory properties contributing to the no-
reflow phenomenon by promoting endothelial edema, neu-
trophil and platelet plugging, microthrombosis, and
increased vasomotor tone.11 Inflammatory mediators12 and
also surgical trauma13,14 activate endothelium to express
tissue factor, thus promoting generation of thrombin
throughout the intravascular space but especially in the
reperfused tissues.9,10 Thrombin, the key enzyme of coag-
ulation, plays a central role between inflammatory and co-
agulation systems. Cytokines enhance thrombin formation
and thrombin activates platelets, endothelium, and leuko-
cytes and forms fibrin from fibrinogen.15,16 All these events
may potentially promote microthrombosis, potentiate reper-
fusion-induced capillary occlusion, and lead to ischemic
organ dysfunction.
Hirudin is a selective and effective inhibitor of thrombin.
In previous studies of inflammation-associated coagulopa-
thy, recombinant hirudin (r-hirudin; lepirudin) blunted en-
dotoxin-induced activation of coagulation in humans17 and
attenuated liver injury in rats.18 In rabbits, r-hirudin signif-
icantly reduced renal fibrin deposits in a model of endotox-
in-induced disseminated intravascular coagulation.19 Ef-
fects of hirudin on CPB-induced ischemia-reperfusion
model have not been studied. We wanted to test in a porcine
model whether r-hirudin could attenuate reperfusion-in-
duced formation of thrombin and whether this inhibition
might have any effect on general hemodynamics or intesti-
nal microcirculation.
Materials and Methods
Animals
Twenty pigs of either sex weighing approximately 26 kg were used
as experimental animals. They were allowed at least 3 days of
in-house acclimatization with ad libitum access to standard labo-
ratory food and water. All animals received humane care in com-
pliance with the “Principles of Laboratory Animal Care” formu-
lated by the National Society for Medical Research and the “Guide
190 The Journal of Thoracic and Cardiovascular Surgery ● Augufor the Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the National
Institutes of Health (NIH Publication No. 86-23, revised 1985). All
experiments were approved by the Local Ethical Committee of
Helsinki University Central Hospital.
Anesthesia
General anesthesia was induced by giving ketamine hydrochloride
500 mg intramuscularly. Two milliliters of pentobarbital sodium, 3
mL of pancuronium bromide, and 0.1 mg of fentanyl citrate were
given intravenously. The pigs were intubated and ventilated with
Siemens Servo Ventilator 900 C (Siemens-Elema AB, Solna,
Sweden) under continuous electrocardiogram (ECG) monitoring
(S/5 Anesthesia Monitor, Datex-Ohmeda, Helsinki, Finland). Gen-
eral anesthesia was maintained with continuous pancuronium pro-
mide (0.25 mg/kg/h), pentobarbital (5 mg/kg/h), and fentanyl
(0.015 mg/kg/h) infusions.
Operative Technique
The left femoral artery and vein were catheterized. Heparin (500
IU/kg) was given just after the vein was catheterized. Arterial
blood pressure was continuously monitored and the femoral vein
was used for intravenous anesthesia. The right femoral vein was
catheterized for infusion of drug or placebo. A small midline
laparotomy was performed and intestinal air-automated 14F
tonometry catheter (Tonometrics Catheter, Datex-Ohmeda) was
inserted into the lumen of ileum 50 cm proximal from the ileocecal
junction and secured with a 5-0 polypropylene purse-string suture.
A midline sternotomy was performed. After sternotomy, the pul-
monary artery was catheterized with a pediatric 5F Swan-Ganz
catheter (Baxter Health Corporation, Santa Ana, Calif) via superior
caval vein. Venous drainage was provided by a cannula in the right
atrium and an aortic perfusion catheter was placed in the aorta. The
left ventricle was catheterized through the apex of the heart for
pressure measurements. After the initial dose of heparin activated
coagulation time (ACT) was measured before CPB and at 30-
minute intervals until 90 minutes post-CPB and an additional dose
(100-200 IU/kg) of heparin was given during perfusion whenever
ACT was below 400 seconds. As a result, 4 animals in the placebo
group and 3 animals in the r-hirudin group received additional
doses of heparin during CPB. Protamine was not given.
A Gambro 2-roller pump (Gambro, Lund, Sweden) and a D 705
miniflow pediatric hollow fiber oxygenator (Dideco, Mirandola,
Italy) were used in all experiments. CPB circuit was primed with
1000 mL Ringersteril (Baxter; Vantaa, Finland) and 5000 IU of
heparin. Hemodynamic, biochemical, and intestinal tonometric
baseline values were determined before normothermic perfusion (2
L/min) was started. The oxygenator was heated with a heat ex-
changer (Heater, Amer Group LTD, Tekamer, Helsinki, Finland),
and temperature was kept at 37.2°C. After the initiation of
perfusion, the aorta was clamped and the heart was arrested with
4°C (15 mL/kg) Plegisol (Abbot Laboratories, North Chicago,
Ill). Myocardial temperature was continuously monitored and a
pericardial insulation pad was used during the crossclamping time.
Cardioplegic solution (2 mL/kg) was added every 15 minutes
and if ventricular fibrillation occurred. Arterial acid-base balance
was monitored during operation at 30-minute intervals (ABL Sys-
tem 615, Radiometer Medical A/S, Copenhagen, Denmark).
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PStudy Setting
In a randomized and blinded manner an intravenous bolus (10 mg,
0.4 mg/kg) of lepirudin (Refludan, Aventis Behring, Marburg,
Germany, and called from hereon “r-hirudin”; n10) or placebo
(20 mL NaCl; n  10) was given 15 minutes before aortic clamp
was released and then continued with a 135-minute intravenous
infusion of r-hirudin (3.75 mg, 0.15 mg/kg) or placebo.
Aortic clamping was released after 1 hour. After clamp release,
ventilation was begun at 7 minutes and the heart was supported by
continuing CPB for 15 minutes. If ventricular fibrillation was
present after 4 minutes, defibrillation was used repeatedly in
1-minute intervals until hemodynamically effective sinus rhythm
was achieved.
Heart rate (HR), ECG, arterial blood pressure (AP), central
venous pressure (CVP), and pulmonary artery pressure were mon-
itored continuously. CVP was standardized before each measure-
ment of the hemodynamic profile. Cardiac output (CO) was ob-
tained simultaneously with HR, pulmonary arterial diastolic
pressure (PADP), pulmonary capillary wedge pressure (PCWP),
AP, left ventricular pressure (LVP), and systemic vascular resis-
tance (SVR) measurements. Inotropic medication was not used.
Blood from mediastinal and pleural spaces was collected and
returned into the CPB system. Blood from the abdomen was
collected into a separate reservoir. Experimental animals were
killed during anesthesia by exsanguination after a surveillance
period of 105 minutes after cessation of CPB.
Hemodynamic Profile
Hemodynamic measurements were obtained before perfusion and
after weaning from CPB and at 15, 30, 60, 90, and 120 minutes
after clamp release. ECG, AP, PADP, CVP, and LVP were mon-
itored continuously. CO measurements were obtained using a
thermodilution method.20 A thermodilution probe was directed
into the main pulmonary artery and connected to a cardiac com-
puter (S/5 Anesthesia Monitor, Datex-Ohmeda). The recorded
value was taken as an average from 3 acceptable measurements.
SVR was calculated using the equation SVR  (mean arterial
pressure  CVP) · 80/CO.
Blood Samples
Blood samples from the catheter inserted through the femoral vein
into the inferior caval vein were obtained before perfusion, just
before aortic declamping, and at 5, 10, 30, and 120 minutes after
aortic clamp was released. Thrombin antithrombin complexes
(TAT) were measured using commercial reagents (Enzygnost TAT
micro, Dade Behring, Liederbach, Germany). ACT was measured
from blood samples obtained from the femoral artery using a
2-channel Automated Coagulation Timer (Medtronic Blood Man-
agement, Parker, Colo).
Tonometric and Blood Gas Measurements
An air-automated tonometry catheter inserted into the ileum in-
cluded a semipermeable silicone balloon at the distal end of the
catheter. Four milliliters of room air was pumped into the silicon
balloon. CO2 freely equilibrated between the intestinal mucosa,
intestinal lumen, and the balloon. The proximal end of the catheter
was connected to a tonometry module (S/5 Tonometry Module,
The Journal of ThoraciDatex-Ohmeda). The system drew a gas sample from the balloon
and intestinal PCO2 (PiCO2) was automatically measured every 10
minutes. Intramucosal pH (pHi) was automatically calculated by
the monitor from PaCO2 and pHa values obtained from arterial gas
analysis, entered by user, and PiCO2 measured. pHi was calculated
by using the equation pHi  pHa  log10 · (PaCO2/PiCO2). Tono-
metric and arterial acid-base values were obtained before perfusion
(0), after 30 minutes of perfusion, just before aortic declamping,
and at 30, 60, 90, and 120 minutes after aortic clamp release.
Bleeding during study drug infusion from the laparotomy
wound and from the intestinal biopsy sites was measured by
collecting blood from abdomen into a separate reservoir. Blood
from the mediastinal and pleural spaces was also measured.
Statistical Methods
Differences between the 2 experimental groups in hemodynamic,
tonometric, and blood gas measurements were statistically evalu-
ated using the repeated measure analysis of covariance model,
which included the baseline value as a covariant. Baseline values
between the 2 experimental groups were compared with 2-tailed
Student t test. Data are presented as mean  standard deviation
(SD).
Results
In the placebo group 1 animal died in the beginning of the
experiment because of a rupture in the aortic root. One
animal died in the placebo group and 1 in the r-hirudin
group at 30 minutes after aortic declamping and 2 in the
r-hirudin group at 90 minutes after aortic declamping be-
cause of a hemodynamic collapse. Eight animals in the
placebo group and 7 animals in the hirudin group survived
until the end of surveillance period.
There were no differences between the placebo and r-
hirudin groups in the time (6.8  2.6 minutes vs 6.2  3.0
minutes, P  .66) needed to achieve regular hemodynam-
ically effective rhythm nor in the number of defibrillations
needed.
Blood Samples
R-hirudin effectively inhibited coagulation as assessed by
ACT. Fifteen minutes after the bolus of r-hirudin ACT was
significantly prolonged in the r-hirudin group compared
with the placebo group (834  231 seconds vs 515  260
seconds, P  .008). Also 15 minutes after weaning from
bypass ACT was significantly longer in the r-hirudin group
when compared with the placebo group (658 335 seconds
vs 274  75 seconds, P  .005). Plasma levels of TAT
increased in both groups during CPB (Figure 1). Notably, in
the placebo group there was a pronounced reperfusion-
associated increase in TAT levels from 30 to 120 minutes
after aortic declamping and the difference between the
experimental groups was significant at 120 minutes (pla-
cebo 75.4  15.6 g/L vs r-hirudin 28.9  7.1 g/L, P 
.001) after aortic declamping (Figure 1).
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CSPHemodynamics
Hemodynamic parameters are presented in Table 1 and in
Figure 2. HR increased slowly but progressively in both
groups toward the end of the surveillance period (Table 1).
CO dropped similarly in both groups but the pigs receiving
r-hirudin showed significantly higher stroke volume (SV)
and CO at 60 minutes and at 90 minutes after aortic
declamping (Figure 2). Importantly, in the r-hirudin group
SV and CO showed recovery toward the preperfusion situ-
ation while in the controls no such trend was observed
(Figure 2). In the placebo group SVR increased markedly
during reperfusion (Figure 2). This reperfusion-induced in-
crease in SVR was effectively abolished in the r-hirudin
group (Figure 2). The difference between the r-hirudin and
placebo groups reached statistical significance at 60 and 90
minutes after aortic declamping (Figure 2). Pulmonary vas-
cular resistance (PVR) was recorded only for some of the
animals. PVR showed a qualitatively similar pattern of
changes as SVR. PVR was significantly higher in the pla-
cebo group at 60 minutes after aortic declamping (990 
337 dyne · s/cm5, n  4, vs 526  191 dyne · s/cm5, n 
8; P  .01).
In both groups, after CPB there were lower systolic,
mean, and diastolic arterial pressures compared with values
before CPB (Table 1). Arterial pressures slowly returned
toward baseline values thereafter but no significant differ-
ence was seen between the 2 groups. In LVP a similar trend
was seen but there was no significant difference between the
2 groups (Table 1).
In the r-hirudin group PADP was higher before CPB,
mainly because 2 animals had exceptionally high (30 mm
Hg) values. During the follow-up PADP increased in both
groups but no significant difference was observed between
Figure 1. The effect of r-hirudin on thrombin-antithrombin (TAT)
complexes during CPB and during reperfusion. Both experimental
groups consisted of 10 animals. P value for comparison between
the 2 experimental groups was calculated with analysis of co-
variance. Values are given as mean  SD. Pre CPB, Before CPB;
0, just before aortic declamping.the 2 groups.
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Data on intestinal tonometry and blood gas analysis are
shown in Figure 3 and in Table 2. Reperfusion was associ-
ated with progressive local mucosal hypoperfusion in both
groups as evidenced by significantly increased PiCO2 and
decreased intestinal pH values in both groups. In the pla-
cebo group but not in the r-hirudin group, there were
changes in curve trends of PiCO2 and pHi at 30 minutes after
aortic declamping but this did not result in significant in-
tergroup differences (Figure 3).
Progressive systemic acidosis observed in both groups
was not due to inefficient oxygenation as arterial O2 in-
creased during CPB but returned to and remained at near
pre-CPB values after CPB in both groups (Table 2).
To evaluate local microcirculatory perfusion in intestinal
mucosa, the gaps between pHa and pHi and PaCO2 and PiCO2
were calculated (Figure 3). Progressive intestinal hypercap-
nia and acidosis developed between 30 and 120 minutes
after the clamp release in the placebo group. Remarkably,
no such local increments in acidosis or hypercapnia were
observed in the r-hirudin group. The rise in P(i-a)CO2 from
30 to 120 minutes postreperfusion was 5.82 6.65 kPa and
0.79  1.7 kPa in the placebo and r-hirudin groups, respec-
tively (P  .044). Corresponding values for pH(a-i) were
0.21  0.21 versus 0.018  0.08 (P  .024).
Hemoglobin significantly decreased in both groups over
time (P  .001) and it was significantly lower in r-hirudin
group at 90 minutes after aortic declamping (Table 2).
Enhanced bleeding was seen in the r-hirudin group (1753
671 mL vs 850  376 mL, P  .007). Bleeding from
mediastinal and pleural spaces, which was returned to CPB
circuit, was 500  236 mL in the placebo group and 1200
 615 mL in the r-hirudin group (P .011). However, only
blood collected from abdominal cavity into a separate res-
ervoir, which was not returned to the animal, presented net
blood loss. This was not significantly different between the
2 groups (530  296 mL vs 325  223 mL, P  .126,
r-hirudin vs controls, respectively).
Discussion
This study tested the hypothesis that direct inhibition of
thrombin could attenuate adverse functional consequences
of ischemia-reperfusion injury. Thrombin is an enzyme with
pleiotrophic effects on cells, including platelets, leukocytes,
endothelial cells, and cardiomyocytes, as well as on several
circulating coagulation factors. On the other hand, clinically
available anticoagulants, including heparin, possess non-
thrombin–related pharmacological effects on plasmatic clot-
ting factors and circulating cells. This makes it most diffi-
cult to study potential pathophysiological significance of
thrombin per se during clinical ischemia-reperfusion injury.
Therefore, we chose to study r-hirudin, the most thrombin-
specific clinical anticoagulant that is not known to possess
st 2004
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complex interacting cellular and enzymatic mechanisms of
ischemia-reperfusion injury may prevent interpreting the
current hemodynamic results as being exclusively due to
isolated thrombin inhibition, leaving open a possibility of
yet unknown non–thrombin-related effects of r-hirudin.
Bearing these reservations in mind, we feel the current
approach to be a feasible effort to better understand the
potential pathophysiological significance of thrombin activ-
ity after CPB.
Transient left ventricular dysfunction due to myocardial
reperfusion injury is a significant and common problem
after cardiac surgery.21 In the control group SV decreased
by 44% after CPB and showed no improvement thereafter.
In remarkable contrast, during early reperfusion animals
receiving r-hirudin could regenerate a significant part of the
lost left ventricular function. At 60 minutes after clamp
release, animals receiving r-hirudin showed 86% of the
preperfusion SV while the corresponding average figure for
control animals was 49%. The mechanisms by which
thrombin inhibition may improve ventricular function re-
main to be determined. However, besides possible attenua-
tion of microcirculatory occlusions by r-hirudin, the current
TABLE 1. Hemodynamic data
Parameter Pre-CPB
15
minutes
HR (beats/min)
Hirudin 134 20 136 16
Placebo 118 13 136 27
P value .06 .2
SAP (mm Hg)
Hirudin 120 18 100 15
Placebo 117 15 96 25
P value .2 .2
MAP (mm Hg)
Hirudin 83 13 58 10
Placebo 80 13 55 8
P value .2 .2
PAPD (mm Hg)
Hirudin 18 10 19 5
Placebo 12 4 17 6
P value .11 .2
LVP (mm Hg)
Hirudin 131 20 114 16
Placebo 131 13 103 27
P value .2 .2
PCWP (mm Hg)
Hirudin 5 2 5 1
Placebo 4 1 5 2
P value .2 .2
HR, Heart rate; SAP, systemic arterial pressure; MAP, mean arterial press
PCWP, pulmonary capillary wedge pressure; Pre-CPB, before cardiopulm
P value for comparison between the experimental groups was calculateddata from the in vivo setting offer logical support to the
The Journal of Thoraciprevious in vitro demonstration that thrombin may directly
inhibit myocyte contractile function.22,23 Thus, improved
thrombin inhibition may be a feasible approach to reduce
myocardial reperfusion injury.
Effects of isolated thrombin inhibition on reperfusion-
induced changes on peripheral microcirculation after CPB
have not been reported previously. In a feline model of
ischemia-reperfusion injury of mesenteric vascular bed, in-
fusion of antithrombin abolished the postischemia increase
in vascular resistance that was observed in control ani-
mals.24 However, as antithrombin may exhibit specific anti-
inflammatory properties distinct from its inhibiting effect on
thrombin,24,25 the contribution of thrombin inhibition to the
improved microvascular flow remained undetermined. In
the current study, infusion of r-hirudin prevented the in-
crease in SVR after CPB that was observed in the control
group. Accordingly, reperfusion seems, indeed, to be asso-
ciated with progressive but transient increase in SVR.24
More importantly, the current data demonstrate that this
phenomenon could effectively be abolished by thrombin
inhibition. This effect could theoretically either improve or
worsen peripheral circulation depending on the compensa-
tory capacity of the heart. Therefore, considering therapeu-
e after aortic declamping
30
utes
60
minutes
90
minutes
120
minutes
 14 136 15 143 20 156 26
 20 151 18 155 25 153 22
06 .08 .14 .2
 11 121 21 125 29 134 20
 23 113 33 123 24 115 14
.2 .2 .2 .20
 17 70 25 70 27 76 19
 9 67 19 74 19 66 17
.2 .2 .2 .2
 8 21 7 24 8 26 5
 6 23 7 25 5 25 6
.2 .2 .2 .2
 19 124 29 127 39 133 28
 23 108 39 122 24 117 21
.2 .14 .2 .2
 2 6 2 5 2 5 1
 2 5 2 5 2 5 2
.2 .2 .11 .02
APD, pulmonary artery diastolic pressure; LVP, left ventricular pressure;
bypass (P value was calculated with Student t test).
analysis of covariance.Tim
min
136
151
.
112
110

64
64

20
17

124
109

5
4

ure; P
onarytic applications of thrombin inhibition during reperfusion, it
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CSPis encouraging that instead of possible systemic hypoten-
sion, myocardium was able to generate better SV and CO
and so compensate peripheral potentially hypotension-pro-
moting effects of r-hirudin. Thus, a net effect most probably
was enhanced flow in various microcirculatory vascular
beds.
CPB results in reduced intestinal intramucosal blood
flow, mucosal acidosis, and dysfunction.4,5,26,27 In animal
studies jejunal and ileal mucosal flow decreased by 38% to
73%4,6 during CPB. Ischemia-reperfusion injury in the in-
testine is characterized by inflammation and capillary plug-
ging.28 In the current study, intestinal tonometry indirectly
assessing tissue oxygenation29 showed progressive intramu-
cosal acidosis during and after CPB, indicating reduced
microvascular blood flow to the intestinal mucosa. How-
Figure 2. The effect of r-hirudin on stroke volume (SV) (A), car-
diac output (CO) (B), and systemic vascular resistance (SVR) (C)
during CPB and during reperfusion. P value for comparison be-
tween the 2 experimental groups was calculated with analysis of
covariance. Values are given as mean  SD. Pre CPB, Before
CPB.ever, because of several confounding factors, quantitating
194 The Journal of Thoracic and Cardiovascular Surgery ● Auguintestinal perfusion should be based on the gap between
arterial and intestinal PCO2 rather than on the intramucosal
pH alone.30-32 In our tonometric measurements the gap
between the intestinal and arterial PCO2 indicated severe
Figure 3. Intestinal pH (pHi) (A) and the gradients for PCO2 [P(i-
a)CO2] (B) and pH [pH(a-i)] (C) between arterial and intestinal
values during CPB and during reperfusion. A significant decrease
during CPB and during reperfusion in pHi was seen over time (P
< .001, analysis of covariance) but no intergroup differences
were observed. Of note, a change in the curve trends of cross-
mucosal PCO2 and pH gradients at 30 minutes after aortic
declamping was observed in the placebo group but not in the
r-hirudin group. None of the intergroup differences were statis-
tically significant. Values are given as mean  SD. Pre CPB,
Before CPB; CPB, 30 minutes after the start of CPB; 0, just before
aortic declamping.splanchnic hypoperfusion. In the previous studies pHi fell
st 2004
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Pduring CPB but after CPB pHi was relatively constant or
slowly began to return back to baseline values.4,6 In con-
trast, we observed a progressive mucosal acidosis through-
out the follow-up. One possible explanation is bleeding seen
in both groups, resulting in decrease in hemoglobin and
relative hypovolemia, which has been shown to induce
splanchnic vasoconstriction and redistribution of the periph-
eral blood flow.33 It has also been shown that during pro-
gressive hemorrhage regional critical hypoperfusion in the
gut (ie, inadequate oxygen supply to meet tissue require-
ments and subsequent metabolic acidosis) develops before
whole-body perfusion is compromised.34 This is consistent
with our observation that although during reperfusion he-
modynamics were well compensated, hypoperfusion of the
gut occurred.
Although r-hirudin evidently did not protect the animals
from intestinal hypoperfusion, significant beneficial effect
could still be demonstrated when compared with the control
animals. The increasing difference between arterial and
intestinal pH during 30 to 120 minutes of reperfusion indi-
cates that microcapillary perfusion significantly deteriorated
in the placebo group while in the r-hirudin group this
phenomenon was not observed. This effect was probably
mostly due to an enhanced cardiac output seen in the r-
hirudin group. In addition, since low hemoglobin reduces
oxygen transport and there was a hemoglobin difference in
favor of the control group, the significance of CO may
further increase.
Although r-hirudin has proven to be a safe and effective
anticoagulant in patients undergoing CPB, difficulties in
TABLE 2. Arterial gas analysis
Parameter
Ti
Pre-CPB CPB 0 minutes
pHa
Hirudin 7.45 0.08 7.35 0.09 7.33 0.08
Placebo 7.42 0.06 7.36 0.09 7.33 0.10
P value .2 .2 .2
PaO2 (kPa)
Hirudin 25.4 7.0 45.5 10.7 44.5 8.5
Placebo 24.6 6.9 46.1 13.2 40.5 11.7
P value .2 .2 .2
PaCO2 (kPa)
Hirudin 5.2 1.1 5.6 0.5 5.8 0.4
Placebo 5.4 0.3 5.5 0.6 5.7 0.6
P value .2 .2 .2
Hb (g/L)
Hirudin 83 11 59 11 65 13
Placebo 87 14 70 9 75 9
P value .2 .08 .14
Pre-CPB, Before cardiopulmonary bypass (P value was calculated with S
P value for comparison between the 2 experimental groups was calculatmonitoring, rather long half-life, possible enhanced bleed-
The Journal of Thoraciing tendency, and lack of specific antidote are clear disad-
vantages of its use in clinical practice. Therefore the current
positive hemodynamic effects of r-hirudin should be taken
as demonstration of potential of improved control of throm-
bin rather than a practical solution for the problem. Specif-
ically, no recommendation for human use of hirudin com-
bined with heparin can be derived from the current study.
Further studies are being conducted to test whether other
thrombin modulators might have the same beneficial effect
with less bleeding.
R-hirudin directly inhibits the active site pocket and
fibrinogen binding site of free and clot-bound thrombin.35,36
R-hirudin, in relative difference to heparin, primarily inhib-
its thrombin activity instead of thrombin generation.37,38
However, thrombin activates several clotting factors and
amplifies its own formation. Thus, blocking thrombin ac-
tivity by r-hirudin might secondarily inhibit further throm-
bin formation.17 Accordingly, in our ischemia-reperfusion
model, direct thrombin inhibition throughout the drug infu-
sion was evidenced by highly prolonged ACT values in the
r-hirudin group. Instead, a statistically significant difference
in the TAT levels developed only at 120 minutes after aortic
declamping when the animals in the placebo group showed
rapid escalation of thrombin formation but animals receiv-
ing r-hirudin did not. Although the more extensive hemodi-
lution in the r-hirudin group may have contributed to the
observed difference in TAT concentration, the data suggest
that r-hirudin may be an effective inhibitor of reperfusion-
induced thrombin formation in addition to being a direct
ter aortic declamping
30 minutes 60 minutes 90 minutes
120
minutes
7.31 0.10 7.30 0.12 7.27 0.17 7.22 0.2
7.32 0.08 7.28 0.08 7.27 0.08 7.26 0.1
.2 .2 .2 .2
20.0 7.1 18.7 6.9 19.3 6.3 18.8 9.2
18.5 7.5 16.0 2.3 14.4 3.8 16.9 5.4
.2 .2 .2 .2
5.6 0.6 5.5 0.5 5.7 0.7 5.9 1.1
5.7 0.4 5.8 0.7 5.6 0.8 5.2 1.3
.2 .2 .2 .11
67 12 60 11 53 13 46 16
72 8 71 12 68 14 63 18
.2 .03 .006 .003
t t test); CPB, during cardiopulmonary bypass.
th analysis of covariance.me af
tudeninhibitor of preformed thrombin.
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CSPIn conclusion, infusion of thrombin inhibitor r-hirudin
during reperfusion was associated with attenuated postisch-
emia left ventricular dysfunction and decreased vascular
resistance. Further studies are needed to clarify whether
these phenomena were extensively thrombin-related or in-
volved other, yet unidentified secondary effects of r-hirudin.
Overall, however, the results suggest that control of coag-
ulation at the level of thrombin activity during ischemia-
reperfusion injury may potentially improve oxygen delivery
to reperfused vascular beds.
We gratefully acknowledge the expert technical assistance by
Janette Sintonen.
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